1	
2	
3	
4	
5	Murine polyomavirus microRNAs promote viruria during the acute
6	phase of infection
7	
8	
9	
10	James M. Burke <sup>1</sup> , Clovis R. Bass <sup>1</sup> , Emin T. Ulug <sup>1</sup> , Christopher S. Sullivan <sup>1,*</sup>
11	
12	*Correspondence:
13	Chris_sullivan@austin.utexas.edu
14	
15	<sup>1</sup> The University of Texas at Austin, Center for Systems and Synthetic Biology, Center for
16	Infectious Disease and Dept. Molecular Biosciences, 1 University Station A5000, Austin TX
17	78712-0162
18	
19	Running title: Polyomavirus miRNAs promote acute viruria
20	Keywords: Polyomavirus, miRNA, viral shedding, viral persistence
21	Abstract word count: 183
22	Manuscript word count: 4,103

#### 23 Abstract

24 Polyomaviruses (PyVs) can cause serious disease in immunosuppressed hosts. Several 25 pathogenic PyVs encode microRNAs (miRNAs), small RNAs that regulate gene expression 26 via RNA silencing. Despite recent advances in understanding the activities of PyV miRNAs, 27 the biological functions of PyV miRNAs during *in vivo* infections are mostly unknown. 28 Studies presented here use murine polyomavirus (MuPvV) as a model to assess the roles of 29 the PyV miRNAs in a natural host. This analysis reveals that a MuPyV mutant that is unable 30 to express miRNAs has enhanced viral DNA loads in select tissues at late times after 31 infection, indicating that during infection of a natural host, PyV miRNAs function to reduce 32 viral replication during the persistent phase of infection. Additionally, MuPyV miRNAs 33 promote viruria during the acute phase of infection as evidenced by a defect in shedding 34 during infection with the miRNA mutant virus. The viruria defect of the miRNA mutant 35 virus could be rescued by infecting Rag2-/- mice. These findings implicate miRNA activity 36 in both the persistent and acute phases of infection and suggest a role for MuPyV miRNA in 37 evading the adaptive immune response.

#### 39 Importance

40 MicroRNAs are expressed by diverse viruses, but for only a few is there any understanding 41 of their in vivo function. PyVs can cause serious disease in immunocompromised hosts. 42 Therefore, increased knowledge of how these viruses interact with the immune response is 43 of possible clinical relevance. Here we show a novel activity for a viral miRNA in promoting 44 virus shedding. This work indicates that in addition to any role for the PvV miRNA in long-45 term persistence, that it also has biological activity during the acute phase. As this mutant 46 phenotype is alleviated by infection of mice lacking an effective adaptive immune response, 47 our work also connects the in vivo activity of a PyV miRNA to the immune response. Given 48 that PyV-associated disease is associated with alterations in the immune response, our 49 findings may help to better understand how the balance between PyV and the immune 50 response becomes altered in pathogenic states.

#### 52 Introduction

53

54 The polyomavirus (PvV) family is comprised of a large number of viruses that predominantly 55 infect vertebrates (1). The founding member of the PyVs, murine polyomavirus (MuPyV), has 56 been the most tractable *in vivo* model for studying the PyV life cycle and has played an important 57 role in understanding PyV-mediated transformation and the antiviral response (2, 3, 4). MuPyV is 58 thought to be transmitted to newborn mice via a respiratory route (5, 6, 7). Primary replication, 59 which occurs 1-6 days post-infection in nonciliated epithelial clara cells of the lungs (7), is 60 followed by dissemination and replication in secondary tissues 7-12 days post infection (6, 8). 61 Viral replication has been observed in various secondary organs, including kidneys, salivary 62 glands, spleen, lymph nodes, heart, liver, skin, lungs, and mammary glands (8, 9, 10). Virus 63 replication peaks around 12 days after infection, concurrent with a rise in viral shedding in the 64 urine and saliva (6). A rise in anti-MuPyV antibody titers occurs 7-15 days p.i. and precedes 65 clearance of detectable virus in most organs by 22-30 days (8).

66

67 A reduction in viral loads marks the transition from the acute phase to the persistent phase, which 68 is generally defined by the continued presence of viral DNA in tissues (3). Viral DNA is 69 maintained in select tissues, such as bone marrow, spleen, kidney, salivary glands, and mammary 70 glands (8, 9). The viral DNA in these tissues is thought to represent a persistent reservoir of 71 'smoldering' viral replication in semi-permissive cells (4), although a latent state has yet to be 72 ruled out. A change in the microenvironment (e.g. tissue damage), immune status (e.g. pregnancy 73 or immunosuppression), or hormone levels (e.g. pregnancy, stress), can 'reactivate' or increase 74 replication of MuPyV from persistent reservoirs (11, 12). This results in episodic shedding of

MuPyV in urine and saliva, which contaminates the surrounding environment with infectious virus
(6). Similar observations have been made for human PyVs, whereby increased viruria during
pregnancy coincides with a rise in anti-PyV neutralizing antibodies (13, 14, 15).

78

79 Many polyomaviruses - including MuPyV, RacPyV, SV40, JCPyV, MCPyV, and BKPyV -80 encode microRNAs (miRNAs) (16, 17, 18, 19, 20), small regulatory RNAs (~22 nt) that repress 81 gene expression via RNA silencing (21). The PvV miRNAs are encoded in the late orientation, 82 opposite to the T antigen mRNAs. Consequently, miRNAs are perfectly complementary to the T 83 antigen transcripts, permitting Argonaute 2 (Ago2)-mediated cleavage of these mRNAs. This 84 results in a reduction in T antigen protein levels late in infection, a conserved function of PyV 85 miRNAs (16, 17, 18, 19, 20, 22). Despite established roles of T antigen in promoting viral 86 replication, miRNA-null laboratory strains of SV40 and MuPyV replicate at rates similar to their 87 wild type counterparts under standard cell culture conditions (16, 17). However, miRNAs 88 expressed by non-rearranged BKPyV strains, which more closely resemble circulating BKPyV in 89 humans and express lower levels of the early transcripts, are able to downregulate T antigen levels 90 to sufficiently reduce viral replication in primary renal proximal tubule epithelial cells (23). 91 Consistent with these results, MCPyV miRNA promotes long-term persistence by inhibiting DNA 92 replication in a cell culture model (24), and the SV40 miRNAs reduce persistent SV40 DNA loads 93 in Syrian Golden hamster tissues (25). These studies suggest that the PyV miRNAs reduce virus 94 replication by down-regulating T antigen expression. However, the effects of miRNA expression 95 on virus replication in a natural host have yet to be established.

97 In addition to regulating viral replication, independent studies implicate a role for the PyV 98 miRNAs in inhibiting the host immune response. Downregulation of T-antigen by the SV40 99 miRNAs decreases CD8 T-cell-mediated lysis in cell culture (16). miRNA-mediated 100 downregulation of the host ULBP3 stress-induced ligand has been suggested to reduce killing of 101 BKV- and JCV-infected cells by natural killer cells (26). MuPyV miRNAs reduce Smad2-102 mediated apoptosis during infection (27). These studies support a model whereby the PyV 103 miRNAs modulate viral and host transcripts in order to extend the life of infected cells by reducing 104 innate and adaptive immune responses.

105

Despite advances in understanding the expression and activities of PyV miRNAs, their functions during the viral lifecycle in a natural host are poorly understood. In this study, we use MuPyV as a model to investigate the role of PyV miRNAs on viral dissemination, replication, and shedding during the acute and persistent phases of infection in mice. This work reveals activities of the MuPyV miRNA in both the persistent and acute phases of infection and suggests a link between miRNA function and the adaptive immune response.

#### 113 **Results**

114

#### 115 Sequencing of the MuPyV miRNAs

MuPyV miRNAs were initially identified via secondary structure predictions and confirmed indirectly (17). This approach could only estimate the 5' and 3' termini of the derivative miRNAs. It also did not resolve whether MuPyV contains additional miRNA loci. To better characterize the MuPyV miRNAs, we conducted high throughput sequencing of small RNA from NIH3T3 cells infected with the MuPyV PTA strain (Figure 1). These results map with precision the termini of the MuPyV miRNAs and confirm that only the single, previously identified pre-miRNA locus, gives rise to MuPyV-encoded miRNA derivatives.

123

## MuPyV miRNAs correlate with reduced viral DNA loads during the persistent phase of infection.

126 PTA-dll013 is a deletion mutant of the MuPyV-PTA strain that does not express miRNAs (17). 127 Previous studies reported that adult C57BL/6 mice infected with PTA-dll013 maintained 128 comparable or slightly higher (up to 5-fold) vDNA loads as compared to PTA in spleen and kidney 129 during the acute phase of infection (up to 34 days p.i.) (17). To confirm these results and determine 130 whether the miRNA function at later times post-infection, we examined MuPyV DNA loads by qPCR in spleens, kidneys, and livers of adult C57BL/6 mice infected with 10<sup>5</sup> IU of PTA or PTA-131 132 dl1013 via IP injection during the acute (1 and 4 weeks p.i.) and persistent (10, 16, and 28 weeks 133 p.i.) phases of infection (Figure 2).

High virus yields (2 x  $10^5 - 5 x 10^6$  genome equivalents/ug DNA) were observed in spleen and kidney after one and four weeks of infection with PTA, consistent with robust virus replication during the acute phase of replication (Figure 2). Lower levels were observed in liver during these times (Figure 2). Virus loads diminished to  $\leq 10^3$  genome equivalents/ug DNA at later times after infection (16 and 28 weeks p.i.), consistent with a low level of virus replication during the persistent phase of replication. These levels were only slightly above the limit of detection of our PCR assay, even when increased input DNA was assayed.

142

143 In comparison to PTA, PTA-dl1013 levels were 4.1-fold lower in spleen, but not kidney, at one 144 week p.i. (Figure 2, closed symbols). No significant differences in PTA and PTA-dl1013 DNA 145 levels were detected at 4 weeks or 10 weeks after infection. However, at 16 weeks, PTA-dl1013 146 genome levels were approximately 10-fold higher than PTA in spleen and kidney. By 28 weeks, 147 only low levels of both PTA and PTA-dl1013 genome levels were detected and no significant 148 differences were observed. These results confirm that the miRNAs are not required for infection 149 and replication in tissues during the acute phase of infection, and indicate that miRNA expression 150 correlates with reduced genomic DNA in certain tissues during the persistent phase of infection.

151

The results summarized in Figure 2 reveal a substantial variation in viral copies between different mice. To minimize variations due to inter-host differences, we compared levels of PTA and PTAdl1013 in individual animals. C57BL/6 mice were co-infected with equivalent amounts of PTA and PTA-dl1013 by IP injection. Tissues were then harvested during the acute (2 and 4 weeks) and persistent (10 and 16 weeks) phases of infection, and genome levels were determined by strainspecific qPCR (Supplemental Figure 1A-C). Similar to individually infected mice, we observed

158 high levels of both PTA and PTA-dl1013 in tissues during the acute phase of infection, with 159 MuPyV levels decreasing during the persistent phase of infection (Figure 3). We note that PTA was not detected in the spleen or kidney by 16 weeks p.i., while PTA-dl1013 was present at  $10^3$  -160 161 10<sup>4</sup> copies/ug DNA (Figure 3). To compensate for variation in different animals, we calculated the 162 ratio of PTA to PTA-dl1013 genomes in individual mice. This analysis reveals that during the 163 acute phase of infection (2 and 4 weeks p.i.), the levels of PTA and PTA-dl1013 were comparable 164 in spleen and kidney (Figure 4). At later times, PTA-dl1013 copy numbers were 10-fold higher 165 than PTA in the spleen and kidney at weeks 10 and 16 and 100-fold higher in the kidney at week 166 16 (Figure 4). We did not observe substantial differences in the liver, but did observe 7-fold higher 167 PTA-dl1013 in the bladder at week 4 (Figure 4). These results are consistent with the elevated 168 levels of PTA-dl1013 detected in the spleen and kidney at 16 weeks following infections with the 169 individual virus strains (Figure 2) and suggest that MuPvV miRNA expression correlates with 170 reduced viral loads in select tissues during the persistent phase of infection.

171

#### 172 MuPyV miRNAs promote viruria during the acute phase of infection.

Early epidemiological studies of MuPyV revealed that high titers of infectious virus are excreted in the urine of mice during the acute phase of infection and then episodically shed during the persistent phase of infection (6). The periodic shedding of MuPyV and many other PyVs in the urine is considered a primary route of transmission (6,28). Therefore, we investigated whether the MuPyV miRNAs affects the magnitude and/or frequency of MuPyV shedding in the urine during the acute and persistent phases of infection. To test this, we collected urine specimens periodically post-infection and quantitated viral genomes. To assess whether PTA-dl1013 could maintain long-

180 term persistence, we treated mice with cyclosporine at day 474 post-infection in order to 181 immunosuppress the mice, which is correlated with increased PyV replication (4).

182

In the majority of mice individually infected with PTA or PTA-dl1013, we observed vDNA shedding of both strains during the acute phase of infection (13-34 days p.i.) (Supplemental Figure 2), indicating that the MuPyV miRNAs are not required for establishing viruria. Both strains were episodically shed throughout the persistent phase (34-87 day p.i.), which demonstrates that the MuPyV miRNAs are not required for persistent viruria (Supplemental Figure 2). The magnitude and timing of virus shedding by individual mice infected varied substantially (Supplemental Figure 2), and thus no statistical differences between PTA and PTA-dl1013 levels could be determined.

190

191 To circumvent the differences in shedding due to variations between individual mice, we tested 192 whether expression of miRNA could correlate with viral shedding in mice co-infected with both 193 PTA and PTA-dl1013. Adult C57BL/6 female mice were co-infected with equal amounts of the 194 PTA and PTA-dl1013, and PTA and PTA-dl1013 DNA was quantitated during the acute and 195 persistent phases of infection (Figure 5A). We did not detect substantial quantities of either PTA 196 or PTA-dl1013 genomes in the urine of  $\sim 40\%$  of the mice at any time point during the acute phase 197 of infection (Supplemental file). The remaining "high-shedder" mice expressed readily detectable 198 MuPyV DNA in the urine. MuPyV in these samples was detected at high levels beginning by 10 199 days p.i. and peaked between 13-27 days, after which the number of shedding mice and the 200 magnitude of shedding began to decrease. Thereafter, we observed episodic shedding events 201 throughout the persistent phase of infection (34-87 days p.i.). These findings reveal that while some mice rarely or never shed detectable virus under our assay conditions, ~60% that are competent for acute and persistent viruria.

204

205 The median PTA levels were significantly higher (5- to 100- fold) than PTA-dl1013 during the 206 majority of the acute phase of infection (10, 13, 15, 17, 20 and 27 days p.i.) in co-infected mice 207 (Figure 5A). To minimize the variance in individual mice, we determined the ratio of PTA:PTA-208 dl1013 DNA in each individual mouse. This data confirmed that PTA was shed at significantly 209 higher levels on average (~10-fold) than PTA-dl1013 during days 10-17 of the acute phase of 210 infection in individual mice co-infected mice (Figure 5B). We did not observe statistically 211 significant differences in the magnitude of viral shedding at the majority of times tested during the 212 persistent phase of infection (Figure 5A, 5B, Supplemental file). Although this may be due to high 213 variance in the timing and the magnitude of shedding, as well as the lower number of mice tested, 214 this suggests that the MuPyV miRNAs do not promote viruria during the persistent phase of 215 infection. In fact, we observed eighty-four PTA-dl1013 shedding events that were above the limit 216 of detection from days 34 through 87, compared to thirty-three for PTA (Figure 5A). This implies 217 that the MuPyV miRNAs may limit detectable shedding during persistent phase of infection, 218 consistent with the reduced PTA levels in tissues (Figures 2-4). At late times post-infection (467-219 492), we observed PTA and PTA-dl1013 shedding events in a small number of mice. Thus, the 220 MuPyV miRNAs are not required to maintain long-term persistent infections. These data further 221 indicate that the MuPyV miRNAs promote viral shedding during the acute phase of infection, but 222 limit the number of MuPyV shedding event during the persistent phase of infection.

223

#### 225 The shedding defect of miRNA-null MuPyV is mitigated in Rag2-/- mice.

226 The host immune response plays an important role in controlling MuPyV infection (2-4), and two 227 lines of evidence suggest that PyV miRNAs may function to reduce the adaptive immune response. 228 First, miRNA-mediated down-regulation of T-antigens decreases susceptibility to cytotoxic T-229 cell-mediated lysis to SV40-infected cultured cells (16). Second, miRNA-null strains of SV40 and 230 JCV have only been isolated from severely immunocompromised hosts, suggesting that an active 231 immune response provides selective pressure to maintain miRNA expression (29). Since the 232 absence of the MuPyV miRNA results in decreased virus shedding during the acute phase of 233 infection, we tested whether the defect in acute viral shedding of PTA-dl1013 is mitigated in 234 C57BL/6 Rag2-/- mice, which lack mature T- and B- cells. C57BL/6 Rag2-/- mice were co-235 infected with PTA and PTA-dl1013, and the shedding of DNA in urine was monitored. Unlike 236 wild type mice, where  $\sim 40\%$  of animals did not shed detectable vDNA during the acute phase of 237 infection, all infected C57BL/6 Rag2-/- mice shed detectable levels of MuPyV by 10 days post-238 infection (Figure 6 and Supplemental file). Levels of both PTA and PTA-dl1013 DNA in urine 239 were found to continually increase in the co-infected C57BL/6 Rag2-/- mice up to 20 days p.i., whereas MuPyV levels leveled off and began to decrease by 20 days p.i. (Figure 6). These 240 241 observations are consistent with the host adaptive immune response being a major factor that 242 controls MuPyV shedding. Importantly, unlike in wild type C57BL/6 mice, C57BL/6 Rag2-/- mice 243 shed PTA-dl1013 DNA at levels similar to PTA during the acute phase of infection (10-13 days 244 p.i.) (Figure 6). These data indicate that the MuPyV miRNAs promote viruria during the acute 245 phase of infection in a manner that is dependent on the host having an intact adaptive immune 246 response.

#### 248 **Discussion**

249

250 The natural in vivo functions of PyV miRNAs are poorly understood. Results presented here reveal 251 that, consistent with previous studies in cell culture models and a non-natural host (23-25), the 252 PyV miRNAs function to reduce viral loads during the persistent infection of a natural host. In 253 addition, we uncover novel effects of the MuPyV miRNAs on viruria during the persistent and 254 acute phases of infection that provide new insights into PyV miRNA biology. 255 256 Similar to previous studies (17), we did not observe large differences in the gross levels of PTA 257 (wild type) and PTA-dl1013 (miRNA-null) strains of MuPyV in tissues during acute phase of 258 infection (weeks 1, 2 and 4 p.i.). This further confirms that the MuPyV miRNAs are not required 259 for acute viral infection and replication *in vivo* under laboratory conditions. However, at weeks 10

and 16 p.i., we observed higher levels of PTA-dl1013 DNA, relative to PTA, in kidney and spleen of mice following single- or co-infection with PTA and PTA-dl1013 (Figures 2-4). Similar findings were observed in tissues of Syrian golden hamsters infected with miRNA-null strains of the simian virus SV40 (25). These results are consistent with the notion that miRNA-mediated downregulation of T antigen reduces virus replication in specific tissues/cell-types at late times after infection to promote viral persistence (23,24).

266

Our assessment of MuPyV viruria revealed that the MuPyV miRNAs are not required to establish or maintain long-term viral persistence (Figure 5 and Supplemental Figure 2). However, we did observe more PTA-dl1013 than PTA shedding events during the persistent phase of infection (34-87 days p.i.). This is consistent with increased PTA-dl1013 levels in tissues and further indicates

that the MuPyV miRNAs may limit viral replication events during the persistent phase of infection. Though the function of this activity remains unclear, it may be important to prevent priming of the host immune response in order to transmit to naïve hosts more efficiently. Alternatively, this activity could prevent viral-associated pathologies to the host, which would presumably decrease viral fitness. Future experiments will address the relevant role of miRNA-mediated reduction of viral loads in urine and tissues during the persistent phase of infection.

277

278 During the acute phase of infection (days 10-20) in wild type C57BL/6 mice, only ~60% of mice 279 shed substantial levels of MuPyV DNA (Figure 5 and Supplemental Figure 2). This is in contrast 280 to infections in immunodeficient C57BL/6 Rag2-/- mice, in which 100% of mice shed substantial 281 levels of MuPyV DNA. This suggests that the adaptive immune response is a major factor 282 controlling viruria. Analysis of wild-type C57BL/6 mice co-infected with PTA and PTA-dl1013 283 revealed that PTA-dl1013 DNA was shed at significantly lower levels than PTA (Figure 5), which 284 indicates the MuPyV miRNAs promote viral shedding at early times post-infection. Importantly, 285 the defect in PTA-dl1013 was largely mitigated during infection of immunodeficient C57BL/6 286 Rag2-/- mice (Figure 6), suggesting that the MuPyV miRNAs help evade a component of the host 287 adaptive immune response to promote viruria. We note that PTA-dl1013 shedding was not fully 288 rescued by infecting C57BL/6 Rag2-/- mice, possibly indicating that the MuPyV miRNAs have 289 additional activities [for example, reduction of smad2-mediated apoptosis (27)] in promoting 290 viruria independent of the adaptive immune response. These combined data demonstrate that the 291 MuPyV miRNAs promote viral shedding by at least indirectly interacting with the adaptive 292 immune response. This activity could be important in the wild as a means to increase transmission 293 of the virus to susceptible hosts during the acute phase of infection.

294

295 The exact mechanism(s) by which MuPyV miRNA expression enhances virus shedding in 296 immunocompetent mice remains unclear. Because we observed miRNA-dependent promotion of 297 shedding in co-infected immunocompetent mice, this indicates that MuPyV miRNAs are likely 298 functioning via a cell autonomous mechanism to repress the effects of the adaptive immune 299 response. This is consistent with previous findings that the SV40 miRNAs can reduce CD8 T-cell-300 mediated lysis. However, it is unclear why the miRNAs promote viruria only during a narrow 301 window of time post-infection. One possibility is that the MuPyV miRNAs increase dissemination 302 to the target cells required for subsequent viruria, possibly by reducing the CTL response to 303 promote infection/replication in lymphocytes early during the acute phase of infection. In support 304 of this, at one week p.i., but not at 2 and 4 weeks p.i., we observed ~4-fold higher PTA DNA levels 305 specifically in the spleen (Figures 2-4), indicating the MuPyV miRNAs may promote infection of 306 lymphocytes early during infection. Alternatively, the cell-mediated adaptive immune response to 307 MuPyV may change over time, making the miRNAs less effective at promoting viruria. While the 308 CD8+ T cell response to MuPyV is predominately to T-antigen, the CD8+ T cell response has also 309 been shown to be directed toward a VP2-derived nonamer peptide (30). Thus, as the infection 310 progresses, miRNA-mediated down-regulate of T-antigens may become less effective at muting 311 the CTL response as the host T-cell response develops more so against the late VP proteins. Future 312 studies are required to more precisely define the relevant components of the immune response 313 important for hindering the miRNA mutant virus.

314

In summary, this study demonstrates functionality of MuPyV miRNAs during both the persistent and acute phases of infection and at least indirectly implicates their function in altering some

- 317 component of the adaptive immune response. Given the clinical relevance of understanding the
- 318 interplay between polyomaviruses and the immune response, this work provides a useful,
- 319 quantitative, and non-invasive system for future efforts at understanding PyV miRNA effects on
- 320 adaptive immunity.
- 321

#### 322 Materials and Methods

323

#### 324 Cell cultures and virus strains

Primary baby mouse kidney (BMK) cell cultures were prepared from 2-4 week old female C57BL/6 mice (Jackson Laboratories). Kidneys were excised, washed in PBS, and incubated in DMEM containing 0.25% trypsin overnight at 4°C. Kidneys were homogenized, incubated in trypsin at 37°C with agitation, and suspended in DMEM+10% FBS (Cellgro). Cells were washed by centrifugation and plated at a density of 10<sup>7</sup> cells per 100 mm dish. NIH3T3 cells were maintained in DMEM+10% FBS.

331

The PTA and PTA-dl1013 virus strains have been described previously (17). Virus was propagated by infecting primary BMK cells (80% confluent) with PTA or PTA-dl1013 at an MOI of 0.05. Virus stocks were prepared after 10 days by scraping the cells into a portion of the culture medium. The cell extracts were then subjected to three freeze/thaw cycles, clarified by centrifugation, and stored at -80°C.

337

Virus titers were determined by immunofluorescence. 80-90% confluent NIH3T3 cells in 12- or 24-well plates were infected with dilutions of the PTA and PTA-dl1013 virus stocks for one hour. Infected cells were maintained in DMEM+2% FBS for 40 hours and then fixed and permeabilized with 4% paraformaldehyde and 1% NP-40. After blocking with 10% goat serum overnight, cells were incubated with rabbit-anti-PyV antibody (a gift from Dr. Richard Consigi) for 30 min. After three PBS washes, cells were stained with Cy3-goat-anti-rabbit IgG (Abcam) for 10 min. and

washed. The numbers of total and stained cells per field were quantified by using an inverted
fluorescent microscope (Leica), and infectious titers (IU/ml) were determined.

346

349

#### 347 Animal infections and tissue analysis

Female C57BL/6 (Jackson Laboratories) and C57BL/6 *Rag2-/-* mice were inoculated with  $1 \times 10^5$ 

IU of either PTA or PTA-dl1013 via intraperitoneal (IP) injection between 4 and 5 weeks of age.

350 For co-infections, mice were inoculated (IP) with 5 x  $10^4$  IU of PTA and 5 x  $10^4$  IU of PTA-

dl1013. Cylcospoin was administered as described in (31). Tissues were harvested at the indicated

times and flash frozen in liquid nitrogen. Homogenates were prepared by grinding with a mortar

and pestle chilled with liquid nitrogen. DNA was extracted from 25 mg of tissue by using the DNeasy Blood and Tissue kit (Qiagen). Recovered DNA was quantitated by the Nanodrop procedure and diluted to 100 ng/ul or 10 ng/ul for qPCR analysis.

356

#### 357 Urine analysis

To collect urine, mice were placed on wire-bottomed cages for 2-4 hours. Urine was collected on Parafilm, and 50 ul aliquots (or the total if less than 50 ul) were used for DNA extraction with the QIAamp viral RNA mini kit (Qiagen) following the manufacturer's protocol to remove PCR inhibitors. DNA was eluted in 60 ul of TE buffer. MuPyV copy numbers were normalized to that in 2 ul of urine.

363

#### 364 **Quantitative PCR**

Concentrated pBluescript-sk+PTA and pBluescript-sk+PTA-dl1013 vectors were obtained via
 Maxi Prep (Invitrogen). Plasmids were prepared at 85.5 ng/ul (10<sup>10</sup> copies of PTA or PTA-dl1013

367 per ul) and then serial diluted. For tissue analysis from individually infected mice, 20 ng of DNA (for samples taken 1, 4, 10 weeks p.i.) or 200 ng of DNA (10 and 28 weeks p.i.) in 2 ul of TE 368 369 buffer was added to an 8 ul reaction mixture containing 5 ul of 2X gene expression master mix 370 (Applied Biosystems), 0.75 uM of MuPyV sense primer (CGCACATACTGCTGGAAGAAGA), 371 1.0 uM MuPyV antisense primer (TCTTGGTCGCTTTCTGGATACAG), and 100 nM of MuPyV 372 TaqMan MGB (Applied Biosystems) probe (FAM-ATCCTTGTGTGCTGAGCCCGATGA-373 NFQ) as described (32). For specific detection of PTA and PTA-dl1013 in urine, 2 ul of DNA (of 374 the 60 ul extracted unless otherwise indicated in Supplemental file) was added to an 8 ul reaction 375 mixture containing 5 ul 2X gene expression master mix (Applied Biosystems), 0.75 uM of 376 PTA/PTA-dl1013 sense primer (GATGAGCTGGGGTACTTGT), 0.75 uM of PTA/PTA-dl1013 377 antisense primer (TGTATCCAGAAAGCGACCAAG), and 100 nM of either the PTA-specific 378 TaqMan MGB (Applied Biosystems) probe (FAM-TAGGATGTCCAAATACAGATCCTC-379 NFQ) or PTA-dl1013-specific TaqMan MGB (Applied Biosystems) probe (FAM-CTCCGGTTCCATTGGCATGT-NFQ). The PTA and PTAdl1013 standards  $(10^7/\text{ul} - 10^1/\text{ul})$  were 380 381 confirmed by using the universal MuPyV primers/probe, which detects both PTA and PTA-382 dl1013, to ensure that the copy number of each standard was equal. Assays were performed using 383 384-well format plates in a ViiA<sup>TM</sup> 7 Real-Time PCR System (Applied Biosystems). The limit of 384 detection was 10 copies.

385

#### 386 Statistical analyses

387 One sample T-test (two-tailed) and Mann-Whitney U-test (two-tailed) were performed using real 388 statistics resource package for excel (http://www.real-statistics.com/).

## **References**

390	1.	Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, Major EO, Ramqvist
391		T, Norkin LC. 2011. Taxonomical developments in the family Polyomaviridae. Arch Virol
392		156: 1627–1634.
393	2.	Benjamin TL. 2001. Polyoma virus: old findings and new challenges. Virology 289: 167-173.
394	3.	Ramqvist T, Dalianis T. 2009. Murine polyomavirus tumour specific transplantation antigens
395		and viral persistence in relation to the immune response, and tumour development. Semin
396		Cancer Biol 19: 236–243.
397	4.	Swanson PA, Lukacher AE, Szomolanyi-Tsuda E. 2009. Immunity to polyomavirus infection:
398		The polyomavirus-mouse model. Semin Cancer Biol 19: 244-251.
399	5.	Rowe WP, Hartley JW, Brodsky I, Huebner RJ, Law LW. 1958. Observations on the spread
400		of mouse polyoma virus infection. Nature 182:1617-16179.
401	6.	Rowe W P. 1961. The epidemiology of mouse polyoma virus infection. Bacteriol Rev 25:18-
402		31.
403	7.	Gottlieb K, Villarreal LP. 2000. The Distribution and Kinetics of Polyomavirus in Lungs of
404		Intranasally Infected Newborn Mice. Virology 266: 52-65.
405	8.	Dubensky TW, Villarreal LP. 1984. The primary site of replication alters the eventual site of
406		persistent infection by polyomavirus in mice. J Virol 50: 541-546.
407	9.	Wirth JJ, Amalfitano A, Gross R, Oldstone MB, Fluck MM. 1992. Organ- and age-specific

replication of polyomavirus in mice. J Virol 66:3278-86.

- 409 10. Berke Z, Dalianis T. 1993. Persistence of polyomavirus in mice infected as adults differs from
  410 that observed in mice infected as newborns. J Virol 67: 4369-4371.
- 411 11. Atencio IA, Shadan FF, Zhou XJ, Vaziri ND, Villarreal LP. 1993. Adult mouse kidneys
- 412 become permissive to acute polyomavirus infection and reactivate persistent infections in
- 413 response to cellular damage and regeneration. J Virol 67: 1424–1432.
- 414 12. McCance DJ, Mims CA. 1979. Reactivation of polyoma virus in kidneys of persistently
  415 infected mice during pregnancy. Infect Immun 25: 998–1002.
- 416 13. Coleman DV, Gardner SD, Mulholland C, Fridiksdottir V, Porter AA, Lilford R, Valdimarsson
- 417 H. 1983. Human polyomavirus in pregnancy. A model for the study of defense mechanisms to
- 418 virus reactivation. Clin Exp Immunol 53: 289-296.
- 419 14. Eash S, Manley K, Gasparovic M, Querbes W, Atwood WJ. 2006. The human polyomaviruses.
  420 Cell Mol Life Sci 63:865-876.
- 421 15. Gibson PE, Field AM, Gardner SD, Coleman DV. 1981. Occurrence of IgM antibodies against
- 422 BK and JC polyomaviruses during pregnancy. J Clin Pathol 34: 674-679.
- 423 16. Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D. 2005. SV40-encoded
  424 microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells.
  425 Nature 435: 682-686.
- 426 17. Sullivan CS, Sung CK, Pack CD, Grundhoff AT, Lukacher AE, Benjamin T, Ganem D. 2009.
  427 Murine polyomavirus encodes a microRNA that cleaves early RNA transcripts but is not
  428 essential for experimental infection. Virology 387: 157-167.
- 429 18. Seo GJ, Chen CJ, Sullivan CS. 2009. Merkel cell polyomavirus encodes a microRNA with the
  430 ability to autoregulate viral gene expression. Virology 383: 183-187.

- 431 19. Seo GJ, Fink LH, O'Hara B, Atwood WJ, Sullivan CS. 2008. Evolutionarily conserved
  432 function of a viral microRNA. J Virol 82: 9823-9828.
- 433 20. Chen CJ, Cox JE, Azarm K, Wylie KN, Woolard KD, Pesavento PA, Sullivan CS. 2015.
- 434 Identification of a Polyomavirus microRNA Highly Expressed in Tumors. Virology 476: 43–
- 435 53.
- 436 21. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281437 297.
- 438 22. Chen CJ, Cox JE, Kincaid RP, Martinez A, Sullivan CS. 2013. Divergent MicroRNA
- 439 Targetomes of Closely Related Circulating Strains of a Polyomavirus. J Virol 87:11135-11147.
- 440 23. Broekema NM, Imperiale MJ. 2013. miRNA regulation of BK polyomavirus replication during
  441 early infection. Proc Natl Acad Sci U S A 110: 8200-8205.
- 442 24. Theiss JM, Günther T, Alawi M, Neumann F, Tessmer U, Fischer N, Grundhoff A. 2015. A
- 443 Comprehensive Analysis of Replicating Merkel Cell Polyomavirus Genomes Delineates the
- 444 Viral Transcription Program and Suggests a Role for mcv-miR-M1 in Episomal Persistence.
- 445 PLoS Pathog 11:e1004974.
- 446 25. Zhang S, Sroller V, Zanwar P, Chen CJ, Halvorson SJ, Ajami NJ, Hecksel CW, Swain JL,
- Wong C, Sullivan CS, Butel JS. 2014. Viral MicroRNA Effects on Pathogenesis of
  Polyomavirus SV40 Infections in Syrian Golden Hamsters. PLoS Pathog 10: e1003912.
- 449 26. Bauman Y, Nachmani D, Vitenshtein A, Tsukerman P, Drayman N, Stern-Ginossar N, Lankry
- 450 D, Gruda R, Mandelboim O. 2011. An identical miRNA of the human JC and BK polyoma
  451 viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host
- 452 Microbe 9:93-102.

453	27. Sung SK, Yim H, Andrews E, Benjamin TL. 2014. A Mouse Polyomavirus-encoded
454	microRNA Targets the Cellular Apoptosis Pathway through Smad2 Inhibition. Virology 468-
455	470: 57-62.

- 456 28. Gosert R, Rinaldo CH, Funk GA, Egli A, Ramos E, Drachenberg CB, Hirsch HH. 2008.
- 457 Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant
- 458 patients and increase viral replication and cytopathology. J Exp Med 205:841–852.
- 459 29. Chen CJ, Burke JM, Kincaid RP, Azarm KD, Mireles N, Butel JS, Sullivan CS. 2014. Naturally
- 460 Arising Strains of Polyomaviruses with Severely Attenuated MicroRNA Expression. J Virol
  461 88:12683-12693.
- 462 30. Swanson PA, Pack CD, Hadley A, Wang C-R, Stroynowski I, Jensen PE, Lukacher AE. 2008.
- An MHC class Ib–restricted CD8 T cell response confers antiviral immunity. J Exp Med
  205:1647–1657.
- 31. Gattazzo F, Molon S, Morbidoni V, Braghetta P, Blaauw B, Urciuolo A, Bonaldo P. 2014.
  Cyclosporin A Promotes in vivo Myogenic Response in Collagen VI-Deficient Myopathic
  Mice. Front Aging Neurosci 244.
- 468 32. Kemball CC, Lee ED, Vezys V, Pearson TC, Larsen CP, Lukacher AE. 2005. Late priming
  and variability of epitope-specific CD8+ T cell responses during a persistent virus infection. J
  470 Immunol.174:7950–60.

## 472 Acknowledgements

- 473 The work described in this article was supported by a Burroughs Wellcome Investigators in
- 474 Pathogenesis Award to CSS and a grant from the Cancer Prevention and Research Institute of
- 475 Texas [RP140842]. The authors would like to thank Dr. Lauren Ehrlich and Dr. Edward
- 476 Marcotte for reagents, and Dr. Luis Villarreal for insights regarding viral persistence.

#### 478 Figure Legends

#### 479 Figure 1. Identification of MuPyV miRNAs by small RNA sequencing.

NIH3T3 cells were infected with MuPyV-PTA at an MOI of 0.1. A small RNA library was prepared 7 days p.i. Dots on the graph represent the read counts of the 5' end of small RNA reads mapping to the MuPyV-PTA genome (NCBI accession number: U27812), positioned on the xaxis. The arrow below the graph represents the pre-miRNA hairpin position and direction. The MuPyV-PTA reference sequence encoding the miRNAs is indicated. Sequences of the three most abundant small RNAs mapping to the 5-prime (bold/red) and 3-prime (bold/blue) arms of premiRNA hairpin are shown aligned to the pre-miRNA. Numbers represent the read counts.

# Figure 2. Quantitation of PTA and PTA-dl1013 during the acute and persistent phases of infection.

489 Adult C57BL/6 female mice were inoculated with 1X10<sup>5</sup> IU of either PTA (white circles) or PTA-490 dl1013 (gray circles) via IP injection, and genome levels in spleen and kidney were quantified at 491 times post infection by using a TaqMan probe and primers that recognize both genomes. The limit 492 of detection for the qPCR reactions was 10 copies. The input DNA amounts were 20 ng (at 1, 4, 493 and 10 weeks p.i.), 40 ng ( at 16 weeks), or 200 ng (at 28 weeks). Genome copy numbers were 494 normalized per lug. Dots represent individual animals. The black bar represents the average 495 genome copy number. The gray bars represent the limit of detection (L.O.D,) of the assay after 496 normalization. Samples that were below the limit of detection are graphed at the limit of detection. 497 P-values were calculated using the Mann-Whitney U test.

#### 498 Figure 3. Quantitation of PTA and PTA-dl1013 in tissues of co-infected mice.

499 qPCR analysis of PTA and PTA-dl1013 genome levels in the spleen, kidney, liver, and bladder of 500 adult C57BL/6 mice inoculated with  $5x10^4$  IUs of PTA and  $5x10^4$  IUs of PTA-dl1013 via IP 501 injection. Tissues were harvested at indicated time points. DNA was recovered and subject to 502 qPCR analysis using PTA- and PTA-dl1013- specific probes. The limit of detection (L.O.D.) was 503 10 copies. Samples in which PTA or PTA-dl1013 were below the limit of detection were graphed 504 at the limit of detection. The quantities were normalized to 1-ug of total DNA. P-values were 505 determined using Mann-Whitney U test.

#### 506 Figure 4. Ratio of PTA and PTA-dl1013 in tissues of co-infected mice.

507 The ratio of PTA and PTA-dl1013 genome copies from (A) in the indicated organs of individual 508 mice co-infected with PTA and PTA-dl1013. Values below the limit of detection were set at the 509 limit of detection. The dots represent Log<sub>10</sub>(PTA/PTA-dl1013). P-values were calculated using 510 one-sample t-test.

#### 511 Figure 5. Quantitation of PTA and PTA-dl1013 DNA shedding in the urine.

Mice were co-infected with  $5x10^4$  IU of PTA and  $5x10^4$  IU of PTA-dl1013 via IP injection, urine 512 513 samples were collected at the indicated times, and strain-specific qPCR was used to quantify wt 514 and mutant genomes. The number of mice tested at each time ranged from 18-30 mice during days 515 1-27 p.i., 10-20 mice during days 29-55 p.i., and 4 mice during days 62-492 p.i. Panel A presents 516 a dot plot of genome equivalents of PTA (blue circles) and PTA-dl1013 (yellow triangles) in 2 ul 517 of urine from mice that shed viral genome copies equal to or greater that the limit of detection of 518 the qPCR assay. Mice that did not shed above the limit of detection or time points in which 519 genomes were not detected were not included in this analysis. Lines represent the median values of PTA (solid blue) and PTA-dl1013) (dotted yellow). Significant differences ( $P \le 0.05$ ) between PTA and PTA-dl1013 genome levels are marked by asterisks. Panel B compares the ratio of wt and mutant genomes in individual mice co-infected with PTA and PTA-dl1013. When only one genome could be detected (either PTA or PTA-dl1013), the other genome was set at the limit of detection in order to calculate the PTA/PTA-dl1013 ratio. The line represents the average log10(PTA/PTA-dl1013) ± SEM. P values were calculated by using a one sample t-test (asterisks indicate  $P \le 0.05$ ).

#### 527 Figure 6. Analysis of PTA and PTA-dl1013 shedding in C57BLC57bl/6 *Rag2-/-* mice.

Nine female C57BL/6-RAG2-/- mice were co-infected with  $5 \times 10^4$  IU of PTA and  $5 \times 10^4$  IU of PTA-dl1013 via IP injection. Urine was collected during the acute phase of infection, and genomic DNA was quantified by strain-specific qPCR analysis. Wild type C57BL/6 mice co-infected with PTA (blue circles/dashed line) and PTA-dl1013 virus (yellow triangles/dashed line) are from Figure 6. PTA genomes (blue circles/solid line) and PTA-dl1013 virus (yellow triangles/solid line) from C57BL/6-Rag2-/- mice are presented. Plots represent the average (±SEM, n=8-9) at the indicated times.




Figure 1




Figure 2





Figure 3



Weeks post-infection

Figure 4




Figure 5




Figure 6